<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5573">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076722</url>
  </required_header>
  <id_info>
    <org_study_id>AS1965</org_study_id>
    <nct_id>NCT04076722</nct_id>
  </id_info>
  <brief_title>Neurotrophic Indicators of Cognition, Executive Skills, Plasticity, and Adverse Childhood Experiences Study</brief_title>
  <acronym>NICE SPACES</acronym>
  <official_title>Neurotrophic Indicators of Cognition, Executive Skills, Plasticity, and Adverse Childhood Experiences Study &quot;NICE SPACES&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oklahoma State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oklahoma State University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adverse childhood experiences (ACEs) are repeatedly shown to predict negative biopsychosocial&#xD;
      health outcomes, including obesity. High rates of ACEs in communities are often paralleled by&#xD;
      high obesity rates, and higher ACEs, such as child abuse, have been shown to positively&#xD;
      predict later obesity and use of unhealthy weight control behaviors. Thus, in light of the&#xD;
      high prevalence of and potential causal links between early-life stress and obesity, there is&#xD;
      a critical need to further explore the ACEs-obesity relationship in order to understand and&#xD;
      to improve obesity outcomes. Given the adverse impact of ACEs and obesity on brain health,&#xD;
      two potential high impact treatment targets of the ACEs-obesity relationship will be explored&#xD;
      in the proposed pilot study: 1) markers of neurocognition (i.e., executive function; EF) and,&#xD;
      2) brain health/plasticity (i.e., neurotrophins like brain-derived neurotropic factor; BDNF&#xD;
      and glial cell derived neurotrophic factor; GDNF).&#xD;
&#xD;
      Specifically, this trial will be the first to 1) Identify whether brain markers of neural&#xD;
      health (e.g., neurotrophins) are related to ACES and/or neurocognitive EF performance, and 2)&#xD;
      Test whether neuronal or glial neurotrophins predict or change in response to weight loss.&#xD;
      Addressing these two needs advances the science of whether ACEs and EF levels are&#xD;
      differentially related to brain indices of neural and glial health/plasticity. Results of&#xD;
      this pilot may identify a neural substrate and/or profile by which ACEs promote obesity that&#xD;
      may ultimately be more amenable to pharmacologic intervention in order to promote weight loss&#xD;
      outcomes.&#xD;
&#xD;
      This group-treatment trial will assess 48 obese adults randomized to either an 8-week&#xD;
      behavioral weight loss treatment group (n=24) or a wait list control (n=24). Our primary&#xD;
      endpoints are percent reductions in body weight and changes in neurotrophins (e.g., BDNF,&#xD;
      GDNF). Weight and blood specimens will be assessed at baseline, post-treatment (8-weeks), and&#xD;
      follow-up (12-weeks). In testing these endpoints, we will meet the following aims: 1) To test&#xD;
      whether neurotrophins are related to ACEs and executive function (EF), and 2) To test if&#xD;
      neurotrophins predict or change in response to weight loss trajectory.&#xD;
&#xD;
      ****The above description describes the study design that was terminated prematurely due to&#xD;
      Covid-19. The following description is the modified protocol.&#xD;
&#xD;
      The treatment described above was canceled and the present study focused on the baseline&#xD;
      visit. In this visit, participants participated in a stress reactivity protocol, so instead&#xD;
      of looking at change in BDNF, GDNF, and inflammatory markers after weight loss treatment, we&#xD;
      looked at change in BDNF, GDNF, and inflammatory markers after the stress activity task. This&#xD;
      information will tell us about how ACEs status is related to these biomarkers at baseline and&#xD;
      in response to stress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adverse childhood experiences (ACEs) are repeatedly shown to predict negative biopsychosocial&#xD;
      health outcomes, including obesity. High rates of ACEs in communities are often paralleled by&#xD;
      high obesity rates, and higher ACEs, such as child abuse, have been shown to positively&#xD;
      predict later obesity and use of unhealthy weight control behaviors. Thus, in light of the&#xD;
      high prevalence of and potential causal links between early-life stress and obesity, there is&#xD;
      a critical need to further explore the ACEs-obesity relationship in order to understand and&#xD;
      to improve obesity outcomes. Given the adverse impact of ACEs and obesity on brain health,&#xD;
      two potential high impact treatment targets of the ACEs-obesity relationship will be explored&#xD;
      in the proposed pilot study: 1) markers of neurocognition (i.e., executive function; EF) and,&#xD;
      2) brain health/plasticity (i.e., neurotrophins like brain-derived neurotropic factor; BDNF&#xD;
      and glial cell derived neurotrophic factor; GDNF).&#xD;
&#xD;
      Specifically, this trial will be the first to 1) Identify whether brain markers of neural&#xD;
      health (e.g., neurotrophins) are related to ACES and/or neurocognitive EF performance, and 2)&#xD;
      Test whether neuronal or glial neurotrophins predict or change in response to weight loss.&#xD;
      Addressing these two needs advances the science of whether ACEs and EF levels are&#xD;
      differentially related to brain indices of neural and glial health/plasticity. Results of&#xD;
      this pilot may identify a neural substrate and/or profile by which ACEs promotes obesity that&#xD;
      may ultimately be more amenable to pharmacologic intervention in order to promote weight loss&#xD;
      outcomes.&#xD;
&#xD;
      This group-treatment trial will assess 48 obese adults randomized to either an 8-week&#xD;
      behavioral weight loss treatment group (n=24) or a wait list control (n=24). Our primary&#xD;
      endpoints are percent reductions in body weight and changes in neurotrophins (e.g., BDNF,&#xD;
      GDNF). Weight and blood specimens will be assessed at baseline, post-treatment (8-weeks), and&#xD;
      follow-up (12-weeks). In testing these endpoints, we will meet the following aims: Aim 1 - To&#xD;
      test whether neurotrophins are related to ACEs and executive function (EF), and Aim 2: To&#xD;
      test if neurotrophins predict or change in response to weight loss trajectory. To ensure the&#xD;
      success of the trial, we have assembled a team of experts in adult behavioral obesity&#xD;
      treatment (PI: Hawkins, PhD), neurotrophins (Consultant: Vasquez, PhD), and biostatistics&#xD;
      (Consultant: Washburn, PhD). The results of this study will advance the science of&#xD;
      neurocognitive risk of weight loss difficulties and their potential treatment. Our approach&#xD;
      ensures that the neurocognitive testing and weight loss protocol can be delivered by trained&#xD;
      non-experts, improving its scalability and future dissemination potential. The results could&#xD;
      ultimately be used to tailor weight loss treatments such that neurocognitive risk factors&#xD;
      related to ACES are identified early and may ultimately be proactively mitigated early in&#xD;
      treatment to maximize participants' lasting weight loss outcomes.&#xD;
&#xD;
      ****The above description describes the study design that was terminated prematurely due to&#xD;
      Covid-19. The following description is the modified protocol.&#xD;
&#xD;
      The treatment described above was canceled and the present study focused on the baseline&#xD;
      visit. In this visit, participants participated in a stress reactivity protocol, so instead&#xD;
      of looking at change in BDNF, GDNF, and inflammatory markers after weight loss treatment, we&#xD;
      looked at change in BDNF, GDNF, and inflammatory markers after the stress activity task. This&#xD;
      information will tell us about how ACEs status is related to these biomarkers at baseline and&#xD;
      in response to stress.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Actual">December 11, 2020</completion_date>
  <primary_completion_date type="Actual">August 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study condition (weight stigma vs. not stigma) was contained in a blinded envelope that only the confederate had access to. The PI does not know which condition the participant got. And the outcomes assessors did not know the condition.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Neurotrophins - Brain-Derived Neurotrophic Factor (BDNF)</measure>
    <time_frame>Baseline (time 0; pre-stressor), Post-stressor (time 1; 30 minutes), Post-stressor (time 2; 60 minutes), Post-stressor (time 3; 90 minutes), ,</time_frame>
    <description>Changes in BDNF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurotrophins - Glial-Derived Neurotrophic Factor (GDNF)</measure>
    <time_frame>Baseline (time 0; pre-stressor), Post-stressor (time 1; 30 minutes), Post-stressor (time 2; 60 minutes), Post-stressor (time 3; 90 minutes), ,</time_frame>
    <description>Changes in GDNF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Panel - IL-6, IL-1beta, TNF-alpha, IFN-gamma</measure>
    <time_frame>Baseline (time 0; pre-stressor), Post-stressor (time 1; 30 minutes), Post-stressor (time 2; 60 minutes), Post-stressor (time 3; 90 minutes), ,</time_frame>
    <description>Changes in pro-inflammatory cytokines IL-6, IL-1beta, TNF-alpha, INF-gamma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Weight Loss</condition>
  <condition>Wait-List Control</condition>
  <arm_group>
    <arm_group_label>Stress reactivity weight stigma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study arm received a stress reactivity paradigm that involved weight stigma content in the form of an evaluated speech task.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stress reactivity non-weight stigma.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study arm received a stress reactivity paradigm that involved non-weight stigma content in the form of an evaluated speech task.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stress reactivity stimuli</intervention_name>
    <description>An evaluated speech task delivered to participants after baseline testing.</description>
    <arm_group_label>Stress reactivity non-weight stigma.</arm_group_label>
    <arm_group_label>Stress reactivity weight stigma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  an overweight/obese body mass index (BMI = 25 kg/m2 or greater)&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  No use of weight loss medications in the past 3 months,&#xD;
&#xD;
          -  No history of or planning to undergo bariatric surgery during the study period,&#xD;
&#xD;
          -  Not currently pregnant or breastfeeding or planning to become pregnant during the&#xD;
             study period,&#xD;
&#xD;
          -  Not already enrolled in a weight loss program (e.g., Weight Watchers Â®),&#xD;
&#xD;
          -  No significant medical or psychiatric comorbidities, including uncontrolled metabolic&#xD;
             disorders (e.g., thyroid, renal, liver), diabetes, heart disease, stroke, cancer,&#xD;
             eating disorder, psychosis, mania, dementia, etc.,&#xD;
&#xD;
          -  Physician determination that the study is appropriate or safe,&#xD;
&#xD;
          -  Able to comply with the assessment procedures&#xD;
&#xD;
          -  Able to provide informed consent or assent,&#xD;
&#xD;
          -  Not planning to move during study period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Individuals must be biologically female to be eligible for the study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Misty Hawkins, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma State University</name>
      <address>
        <city>Stillwater</city>
        <state>Oklahoma</state>
        <zip>74078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Weight Loss</keyword>
  <keyword>Adverse childhood experiences</keyword>
  <keyword>Executive function</keyword>
  <keyword>Brain health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

